Samuel Chung 1 2, Nathalie Baumlin 1 2, John S Dennis 1 2, Robert Moore 2, Sebastian F Salathe 2, Phillip L Whitney 2, Juan Sabater 3, William M Abraham 3, Michael D Kim 1 2, Matthias Salathe 1 2
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.
2Division of Pulmonary, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, Florida; and.
3Department of Research, Mount Sinai Medical Center, Miami Beach, Florida.
The transient receptor potential ankyrin 1 (TRPA1) is a molecular target for vape effects due to its expression in airway epithelia and its reported gating by nicotine, reactive oxidants, and flavors, especially cinnamaldehyde. To test whether nicotine had effects independent of other e-cig vapor constituents, the Vitrocell® CLOUD exposure system was utilized to nebulize fixed nicotine doses onto the apical surface of ALI cultures. A549 cell cultures were exposed to nicotine containing e-cig vapor, produced by the VC-1 smoke exposure robot, in the air-liquid interface.